Human Genome Epidemiology Literature Finder
Records 1 - 17 (of 17 Records) |
Query Trace: Small Cell Lung Carcinoma and MET[original query] |
---|
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. British journal of cancer 2011 (6): 814-23. Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño J A, Arpí O, Salido M, Menéndez S, Grande E, Hirsch F R, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell |
Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncology reports 2011 Oct 26 (4): 877-85. Cai Yi-Ran, Zhang Hai-Qing, Qu Yang, Mu Jing, Zhao Dan, Zhou Li-Juan, Yan Hong, Ye Jian-Wei, Liu Y |
Mutated ephrin receptor genes in non-small cell lung carcinoma and their occurrence with driver mutations-targeted resequencing study on formalin-fixed, paraffin-embedded tumor material of 81 patients. Genes, chromosomes & cancer 2013 Dec 52 (12): 1141-9. Mäki-Nevala Satu, Kaur Sarhadi Virinder, Tuononen Katja, Lagström Sonja, Ellonen Pekka, Rönty Mikko, Wirtanen Aino, Knuuttila Aija, Knuutila Saka |
Increased NQO1 but not c-MET and survivin expression in non-small cell lung carcinoma with KRAS mutations. International journal of environmental research and public health 2014 Sep 11 (9): 9491-502. Yilmaz Ahmet, Mohamed Nehad, Patterson Kara A, Tang Yan, Shilo Konstantin, Villalona-Calero Miguel A, Davis Michael E, Zhou Xiaoping, Frankel Wendy, Otterson Gregory A, Beall Howard D, Zhao Weiqia |
Morphological and molecular approach to synchronous non-small cell lung carcinomas: impact on staging. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2016 Apr . Schneider Frank, Derrick Veronica, Davison Jon M, Strollo Diane, Incharoen Pimpin, Dacic San |
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Feb . Tong Joanna H, Yeung Sai F, Chan Anthony Wh, Chung Lau Y, Chau Shuk L, Lung Raymond Wai Ming, Tong Carol Y, Chow Chit, Tin Edith Ky, Yu Yau H, Li Hui, Pan Yi, Chak Wing P, Ng Calvin Sh, Mok Tony S K, To Ka |
Relationship between driver gene mutations, their relative protein expressions and survival in non-small cell lung carcinoma in Macao. The clinical respiratory journal 2017 Jul . Chan Kin Iong, Vong Hong Ting, Sin Lai Fong, Yip Yuk Ching, Zhong Xue Yun, Wen Jian Mi |
[Clinical significance and mechanism of upregulation of PI3Kp110? in non-small cell lung carcinoma]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 2017 Oct 39 (10): 737-743. Xiong Y, Qu L L, Li D, Wang Y, Li |
Identification of genome variations in patients with lung adenocarcinoma using whole genome re?sequencing. Molecular medicine reports 2017 10 16 (6): 9464-9472. Li Guiyuan, Mei Yunqing, Yang Fan, Yi Shengming, Wang Lem |
KRAS mutation is predictive of outcome in patients with pulmonary sarcomatoid carcinoma. Histopathology 2018 Feb . Mehrad Mitra, Roy Somak, LaFramboise William A, Petrosko Patti, Miller Caitlyn, Incharoen Pimpin, Dacic San |
How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review. Critical reviews in oncology/hematology 2021 8 166 103459. Torres Gabriel Fernando, Bonilla Carlos Eduardo, Buitrago Giancarlo, Arrieta Oscar, Malapelle Umberto, Rolfo Christian, Cardona Andrés |
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research 2021 8 27 (21): 5781-5792. Camidge D Ross, Morgensztern Daniel, Heist Rebecca S, Barve Minal, Vokes Everett, Goldman Jonathan W, Hong David S, Bauer Todd M, Strickler John H, Angevin Eric, Motwani Monica, Parikh Apurvasena, Sun Zhaowen, Bach Bruce Allen, Wu Jun, Komarnitsky Philip B, Kelly Kar |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C. Targeted oncology 2021 5 16 (3): 339-355. Yoh Kiyotaka, Hirashima Tomonori, Saka Hideo, Kurata Takayasu, Ohe Yuichiro, Hida Toyoaki, Mellemgaard Anders, Verheijen Remy B, Ou Xiaoling, Ahmed Ghada F, Hayama Manabu, Sugibayashi Ko, Oxnard Geoffrey |
Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma-A Retrospective Analysis of a Multicenter Clinical Study. Frontiers in molecular biosciences 2021 5 8 639892. Yang Xue, Xia Yang, Xu Liyan, Liang Li, Zhuo Minglei, Wu Meina, An Tongtong, Wang Ziping, Wang Yuyan, Li Jianjie, Zhong Jia, Chen Hanxiao, Jia Bo, Wang Jingjing, Zhao J |
Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China. Frontiers in oncology 2021 11 630717. Lv Weize, Cheng Hua, Shao Di, Wei Yajun, Zhu Weiping, Wu Kui, Jiang Wenxi, Hu Liyang, Sha Zhou, Zhong Beilong, Pei Xiaofe |
Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective. Pathology, research and practice 2023 12 253 155013. Aditi Aggarwal, Shivani Sharma, Zoya Brar, Vipin Kumar, Akash Kumar, Rahul Katara, Sambit K Mohan |
PDL1 and molecular biomarkers expression in non-small cell lung cancer in Tunisian patients. Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace 2023 11 . Yoldez Houcine, Chirine Moussa, Ahmed Ben Abdelaziz, Aida Aya |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 29, 2024
- Content source: